A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Change from Baseline in Glucose-Stimulated C-peptide Area Under the Curve (AUC)

Time frame: Baseline, Week 52

Change from Baseline in Glucose AUC

Time frame: Baseline, Week 52

Change from Baseline in AUC Ratio (AUC C-peptide/AUC Glucose × 1000)

Time frame: Baseline, Week 52

Change from Baseline in Height

Time frame: Baseline, Week 52

Change from Baseline in Body Mass Index (BMI) Percentile

Time frame: Baseline, Week 52

Change in Glucose Time in Range Between 70 and 180 mg/dL (inclusive)

Time frame: Baseline, Week 52

Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2)

Time frame: Baseline, Week 52

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

Time frame: Predose through Week 24

PK: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib

Time frame: Predose through Week 24

Change from Baseline in Matsuda Index

Time frame: Baseline, Week 52